ZELBORAF Special Drug Use Surveillance (Malignant Melanoma)

ZELBORAF Special Drug Use Surveillance (Malignant Melanoma) - ZELBORAF Special Drug Use Surveillance (Malignant Melanoma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016583

Enrollment

500

Registered

2015-02-26

Start date

2015-02-26

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Melanoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients planning to use Zelboraf during the enrollment period

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Adverse reaction incidence	—

Secondary

Measure	Time frame
Effectiveness OS	—

Countries

Japan

Contacts

Public ContactShinichi Matsuda

Chugai Pharmaceutical Co. Ltd. Safety science Dept

matsudasni@chugai-pharm.co.jp03-3281-6611

Outcome results